Our results suggest inhibiting TRIAD1-substrate RTKs (with nintedanib) substitutes, to some extent, for increased TRIAD1 expression to normalize emergency granulopoiesis in MLL1-ELL-AML. The gene discussed is ARIH2; the disease is acute myeloid leukemia.